CA2068790A1 - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
CA2068790A1
CA2068790A1 CA002068790A CA2068790A CA2068790A1 CA 2068790 A1 CA2068790 A1 CA 2068790A1 CA 002068790 A CA002068790 A CA 002068790A CA 2068790 A CA2068790 A CA 2068790A CA 2068790 A1 CA2068790 A1 CA 2068790A1
Authority
CA
Canada
Prior art keywords
antiviral compounds
formula
hiv
pharmacetical
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002068790A
Other languages
French (fr)
Other versions
CA2068790C (en
Inventor
Janet Mary Cameron
Nicholas Cammack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK Ltd
Original Assignee
Janet Mary Cameron
Nicholas Cammack
Glaxo Group Limited
Viiv Healthcare Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2068790(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919110624A external-priority patent/GB9110624D0/en
Priority claimed from GB919121381A external-priority patent/GB9121381D0/en
Priority claimed from GB919123581A external-priority patent/GB9123581D0/en
Application filed by Janet Mary Cameron, Nicholas Cammack, Glaxo Group Limited, Viiv Healthcare Uk Limited filed Critical Janet Mary Cameron
Publication of CA2068790A1 publication Critical patent/CA2068790A1/en
Application granted granted Critical
Publication of CA2068790C publication Critical patent/CA2068790C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Combinations comprising a compound of formula (1) (see formula I) or a pharmaceutically acceptable derivative. thereof and an inhibitor of HIV
replication, pharmacetical formulations thereof and their use in the treatment of HIV
infections.
CA002068790A 1991-05-16 1992-05-15 Antiviral compounds Expired - Lifetime CA2068790C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9110624.5 1991-05-16
GB919110624A GB9110624D0 (en) 1991-05-16 1991-05-16 Combinations
GB9121381.5 1991-10-08
GB919121381A GB9121381D0 (en) 1991-10-08 1991-10-08 Combinations
GB9123581.2 1991-11-06
GB919123581A GB9123581D0 (en) 1991-11-06 1991-11-06 Combinations

Publications (2)

Publication Number Publication Date
CA2068790A1 true CA2068790A1 (en) 1992-11-17
CA2068790C CA2068790C (en) 2005-06-07

Family

ID=27265656

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002068790A Expired - Lifetime CA2068790C (en) 1991-05-16 1992-05-15 Antiviral compounds

Country Status (25)

Country Link
US (2) US5627186A (en)
EP (1) EP0513917B2 (en)
JP (1) JP2868671B2 (en)
KR (1) KR100246687B1 (en)
CN (1) CN1045961C (en)
AT (1) ATE131730T1 (en)
AU (2) AU1787492A (en)
CA (1) CA2068790C (en)
CZ (1) CZ285232B6 (en)
DE (2) DE69206876T3 (en)
DK (1) DK0513917T4 (en)
ES (1) ES2083668T5 (en)
GR (1) GR3018915T3 (en)
HK (1) HK78897A (en)
IE (1) IE73261B1 (en)
IL (1) IL101883A (en)
LU (1) LU90234I2 (en)
MX (1) MX9202279A (en)
NL (1) NL980018I2 (en)
NO (2) NO301690B1 (en)
NZ (2) NZ242754A (en)
OA (1) OA10058A (en)
SK (1) SK279262B6 (en)
TW (1) TW273550B (en)
WO (1) WO1992020344A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
GB9215178D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (en) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa New oxathiolanes, process for their preparation and pharmaceutical compositions containing them.
TW401303B (en) * 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
AP9801419A0 (en) 1996-06-25 1998-12-31 Glaxo Group Ltd Combination comprising VX478, zidovudine, FTC and or 3
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6495553B1 (en) 1997-08-08 2002-12-17 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
BR9907736A (en) 1998-01-23 2000-10-17 Newbiotics Inc Enzyme-catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
MXPA02000762A (en) 1999-07-22 2002-08-20 Newbiotics Inc Methods for treating therapy resistant tumors.
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
US20050287177A1 (en) * 2002-11-08 2005-12-29 Glaxo Group Unlimited And Smithkline Beecham Corp. Pharmaceutical compositions
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
JP4482883B2 (en) 2003-05-22 2010-06-16 リードケミカル株式会社 Compound having antiviral action and its combination
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
EP1975923B1 (en) * 2007-03-28 2016-04-27 Nuance Communications, Inc. Multilingual non-native speech recognition
EP2435052B1 (en) 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
CN104203275A (en) 2010-06-09 2014-12-10 疫苗技术股份有限公司 Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
RU2014140177A (en) 2012-03-05 2016-04-27 Сипла Лимитед PHARMACEUTICAL ANTIRETROVIRAL COMPOSITIONS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1214611B (en) * 1985-05-22 1990-01-18 Schiena Ricerche COMPOUNDS FOR DERMATOLOGICAL COSMETIC USE AND RELATED COMPOSITIONS.
GB8717955D0 (en) * 1987-07-29 1987-09-03 Fujisawa Pharmaceutical Co Prevention & treatment of aids
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
JPH02504283A (en) * 1988-03-23 1990-12-06 ニューヨーク　ユニバーシィティ Antiviral compositions and methods for treating retroviral infections comprising aromatic polycyclic dione compounds and nucleoside analogs
EP0362359A4 (en) * 1988-03-23 1991-11-21 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
JPH02142733A (en) * 1988-09-28 1990-05-31 Sigma Tau Ind Farmaceut Riunite Spa Aids therapeutic agent containing didobzin
EP0374096B1 (en) * 1988-12-14 1992-12-02 Ciba-Geigy Ag Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
IL93136A (en) * 1989-02-23 1995-01-24 Janssen Pharmaceutica Nv Tetrahydroimidazo (1,4) benzodiazepin-2-thione derivatives, their preparation and pharmaceutical compositions containing them
NZ232912A (en) * 1989-03-17 1992-06-25 Oncogen Ltd Lp Synergistic composition of nucleoside derivatives for inhibiting hiv
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
SE464168B (en) † 1989-07-19 1991-03-18 Bo Fredrik Oeberg ANTIVIRAL COMPOSITION CONSISTING OF A 3'-FLUORO-2 ', 3'-DIDEOXYNUCLEOSIDE COMPOUND AND AND 2', 3'-DIDEOXYNUCLEOSIDE COMPOUND (EXAMPLE AZT)
US5116823A (en) * 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination

Also Published As

Publication number Publication date
NL980018I1 (en) 1998-07-01
ES2083668T5 (en) 2001-06-16
NO1999018I1 (en) 1999-07-22
ATE131730T1 (en) 1996-01-15
SK119993A3 (en) 1994-04-06
US5859021A (en) 1999-01-12
CA2068790C (en) 2005-06-07
NL980018I2 (en) 1998-11-02
DE69206876T2 (en) 1996-05-23
DK0513917T4 (en) 2001-06-25
HK78897A (en) 1997-06-20
CZ242893A3 (en) 1994-07-13
CZ285232B6 (en) 1999-06-16
OA10058A (en) 1996-10-14
DE69206876D1 (en) 1996-02-01
IE921566A1 (en) 1992-11-18
EP0513917B2 (en) 2001-03-07
CN1068570A (en) 1993-02-03
IL101883A (en) 1998-10-30
ES2083668T3 (en) 1996-04-16
NZ299240A (en) 2004-11-26
AU1627992A (en) 1992-11-19
DE69206876T3 (en) 2004-08-12
CN1045961C (en) 1999-10-27
EP0513917B1 (en) 1995-12-20
GR3018915T3 (en) 1996-05-31
IE73261B1 (en) 1997-05-21
NO921947L (en) 1992-11-17
KR100246687B1 (en) 2000-04-01
LU90234I2 (en) 1998-06-24
JP2868671B2 (en) 1999-03-10
WO1992020344A1 (en) 1992-11-26
SK279262B6 (en) 1998-08-05
EP0513917A1 (en) 1992-11-19
IL101883A0 (en) 1992-12-30
NO301690B1 (en) 1997-12-01
DE19875016I2 (en) 2004-07-01
TW273550B (en) 1996-04-01
AU661307B2 (en) 1995-07-20
NO921947D0 (en) 1992-05-15
MX9202279A (en) 1992-11-01
JPH06234641A (en) 1994-08-23
US5627186A (en) 1997-05-06
AU1787492A (en) 1992-12-30
DK0513917T3 (en) 1996-02-05
KR920021148A (en) 1992-12-18
NZ242754A (en) 1996-11-26

Similar Documents

Publication Publication Date Title
CA2068790A1 (en) Antiviral compounds
CA2105487A1 (en) Antiviral nucleoside combination
CA2143107A1 (en) Enantiomerically pure .beta.-d-dioxolane-nucleosides
CA2004598A1 (en) Medicinal aerosol formulations
CA2111002A1 (en) Non-Chlorofluorocarbon Aerosol Formulations
AU2724292A (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-d-neuraminic acid
EP0497258A3 (en) Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer
CA2231194A1 (en) Pharmaceutical formulation
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
CA2211802A1 (en) Pharmaceutical composition for the treatment of herpes
AU650484B2 (en) Isoxazole compound, pharmaceutically acceptable salt thereof, and medicinal use thereof
CA2046069A1 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
CA2114859A1 (en) Cytotoxic and antiviral compound
CA2086756A1 (en) Penciclovir and famciclovir and related guanine derivatives for the treatment of the hiv-1 infections
ES2072386T3 (en) DERIVATIVES OF PENCICLOVIR FOR THE TREATMENT OF HEPATITIS-B INFECTIONS.
AU1662092A (en) Use of a 1,3-oxathiolan derivative for the treatment of hepatitis b infection
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
EP0509098A4 (en) Ataractic
DK0728002T3 (en) Use of 2-aminopurine derivatives for the treatment and prevention of human herpes virus 7 infections
CA2101548A1 (en) Acylamino-alkylidenhydroxy-bisphosphonic acids useful in the therapy of osteoarticular diseases
WO1996027378A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
CA2099667A1 (en) Agent for treating hepatic diseases
CA2176376A1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections
ITRM910522A0 (en) PROCEDURE FOR THE PREPARATION OF A COSMETIC AND/OR PHARMACEUTICAL PREPARATION IN THE FORM OF A WATER-SOLUBLE SPONGOUS FILM, AND WATER-SOLUBLE SPONGOUS FILM AS OBTAINABLE
AU3240493A (en) Compounds and compositions for treating HIV infections

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry